| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Articles |
Presented in part at the 63rd to 66th Scientific Sessions of the American Heart Association (1990-1993).
From the Department of Cardiology, University of Heidelberg (Germany).
Correspondence to Dr Feraydoon Niroomand, Universität Heidelberg, Innere Medizin III, Bergheimerstr 58, 69115 Heidelberg, Germany.
| Abstract |
|---|
|
|
|---|
-35S]GTP to
sarcolemmal membranes, high- and low-affinity binding sites for the
muscarinic antagonist carbachol, the EC50 for
carbachol-stimulated GTPase activity and the substrate dependency of
the high-affinity GTPase, the interaction between muscarinic receptors
and inhibitory G proteins, and GTP binding to G proteins were not
altered (n=14). Immunoblotting with
i- and
i2-specific antibodies did not indicate a loss of
Gi proteins during ischemia that could
explain the reduced GTPase activity. During 15 minutes of
reperfusion, carbachol-stimulated GTPase activity increased to 147% of
the control value (control, 33.7±20.6; reperfusion, 49.1±22.5
pmol · min-1 · mg protein-1; n=7;
P=.012). Maximal inhibition of adenylyl cyclase by carbachol
increased similarly (control, 21±6.8% maximal inhibition;
reperfusion, 26.4±7.6% maximal inhibition; n=8; P=.016).
After 15 minutes of ischemia and 60 minutes of reperfusion,
carbachol-stimulated GTPase activity remained increased. When the
5-minute ischemia and 15-minute reperfusion periods were followed by a
second period of 5-minute ischemia, carbachol-stimulated GTPase
activity and inhibition of adenylyl cyclase remained elevated (GTPase:
control, 38.4±16.7; second ischemia, 49.2±20.1
pmol · min-1 · mg protein-1; n=13;
P=.009; adenylyl cyclase: control, 24.2±6.8% maximal
inhibition; second ischemia, 28.6±8% maximal inhibition; n=15;
P=.003). In conclusion, the responsiveness of Gi
proteins toward receptor activation decreased rapidly during the first
5 minutes of ischemia. During a following 15-minute period of
reperfusion, this decreased responsiveness was reversed completely,
exceeding control activities. The increased responsiveness of this
signaling pathway was maintained during a subsequent second ischemic
period. This suggests that the underlying mechanism of ischemic
preconditioning is the increased responsiveness of Gi
proteins after a brief period of ischemia and reperfusion.
Key Words: myocardial ischemia reperfusion ischemic preconditioning G proteins muscarinic receptors adenylyl cyclase
| Introduction |
|---|
|
|
|---|
However, the underlying mechanisms of myocardial protection in the preconditioned myocardium during ischemia are still unknown. It has been shown very recently that adenosine receptor stimulation not only induces preconditioning during the initial brief period of ischemia but also mediates the protective effect during a subsequent sustained ischemic period.7 However, during every episode of ischemia increased amounts of adenosine are released,8 which are sufficient for maximal activation of A1 receptors.9 Hence, ischemic preconditioning should result in an improved effectiveness of adenosine, and an increased responsiveness of Gi-mediated signaling pathways may be suggested as the underlying mechanism. Accordingly, the influence of ischemia, reperfusion, and subsequent ischemia on the Gi-mediated signal transduction was investigated in the present study.
| Materials and Methods |
|---|
|
|
|---|
To rule out effects that were not related to ischemia (eg, anesthesia), each animal served as its own control, and ischemic and nonischemic tissues were prepared under exactly the same conditions.
Binding of [3H]N-Methylscopolamine
Equilibrium binding of muscarinic receptor antagonists to
purified sarcolemmal membranes was determined by incubation of
[3H]N-methylscopolamine with 3 µg
sarcolemmal protein suspended in 500 µL of a reaction mixture
containing 5 mmol/L MgCl2, 20 mmol/L Tris HCl (pH
7.5), and 5 mmol/L NaH2PO4 (120 minutes at
30°C). The amount of sarcolemmal protein was within the range of a
linear increase of [3H]N-methylscopolamine
binding, regardless of whether sarcolemmal membranes were from ischemic
or nonischemic myocardial tissue. Binding reactions were stopped by
rapid filtration through Whatmann GF/B filters with the use of a
Brandel cell harvester. Filters were washed three times with 3 mL of
ice-cold 50 mmol/L Tris HCl (pH 7.5) and placed in 3 mL scintillation
liquid (Aquasure High Performance LSC Cocktail, Du Pont). Radioactivity
was determined by liquid scintillation spectroscopy (Multi-User LSC LB
5004 6F Betaszint). Specific binding was defined as the difference in
[3H]N-methylscopolamine bound in the absence
and presence of 10 µmol/L atropine sulfate.
Binding of Carbachol
Binding of carbachol was indirectly measured by competition
experiments. Sarcolemmal membranes were preincubated for 30 minutes (pH
7.5, 30°C) in a reaction medium containing 50 mmol/L
Na2HPO4/NaH2PO4,
5 mmol/L MgCl2, the ionophore alamethicin (wt
alamethicin/wt protein=1.0), either with or without 10 µmol/L
(ß,
-imido)-guanosine-5'-triphosphate [Gpp(NH)p]. The reaction
was started by simultaneous addition of
[3H]N-methylscopolamine (final concentration,
500 pmol/L) and increasing amounts of carbachol (final concentrations,
5 nmol/L to 50 µmol/L). The other experimental steps were performed
according to the description of
[3H]N-methylscopolamine binding.
Binding of [
-35S]GTP
To determine binding of [
-35S]GTP, 0.8 to 1.0
µg of sarcolemmal proteins were incubated in a reaction buffer (100
µL final volume) containing 1 µmol/L GDP, 50 mmol/L Tris HCl, 5
mmol/L MgCl2, 1 mmol/L EDTA, 150 mmol/L NaCl, and
[
-35S]GTP/[
-S]GTP at increasing concentrations
(pH 7.5, 30°C). Unspecific binding was determined in the presence of
10 µmol/L unlabeled [
-S]GTP. The binding reaction was started by
addition of sarcolemmal membranes and stopped after 60 minutes by rapid
filtration through Whatmann GF/B filters with the use of a Brandel cell
harvester. The incubation time of 60 minutes was enough to reach
binding equilibrium under ischemic and nonischemic conditions. The
dependence of [
-35S]GTP binding on protein
concentration was linear up to 1 µg protein per 100 µL. The filters
were washed four times with 3 mL of an ice-cold buffer containing 50
mmol/L Tris HCl (pH 7.5) and 5 mmol/L MgCl2 and
subsequently placed in 3 mL scintillation liquid (Aquasure High
Performance LSC Cocktail; Du Pont). Radioactivity was determined by
liquid scintillation spectroscopy as described above.
GTPase Assay
GTPase activity was determined as described by Fleming and
Watanabe.13 GTP hydrolysis was directly assessed by
measuring the release of [32Pi] from
[
-32P]GTP. The transfer of [
-32P]
from GTP to ADP was suppressed by an ATP-regenerating system. The
enzyme reaction was started by the addition of sarcolemmal membranes (3
µg protein per 100 µL assay volume) to the reaction medium
containing 1 mmol/L EDTA, 40 mmol/L Tris HCl (pH 7.5), 0.5 mmol/L ATP,
0.5 mmol/L
(ß,
-imido)-adenosine-5'-triphosphate
[App(NH)p], 1 mmol/L dithiothreitol, 5 mmol/L
MgCl2, 5 mmol/L creatine phosphate, 4 U/L creatine
kinase, 1 mg/mL bovine serum albumin, 0.2 µmol/L GTP, and 36 to 40
nCi [
-32P]GTP (37°C). App(NH)p was used for the
inhibition of nonspecific nucleoside triphosphatases. To suppress basal
ß-adrenoreceptorGs interaction, 10 µmol/L alprenolol
was added to the assay. The reaction was stopped after 10 minutes by
the addition of 900 µL ice-cold activated charcoal suspension (Norit
A, 20 mmol/L phosphoric acid, 5% wt/vol). This mixture subsequently
was centrifuged at 2500g (10 minutes, 4°C), and 500 µL
of the supernatant was added to 4 mL Tris HCl (pH 7.5). The amount of
hydrolyzed [32P]phosphate in the solution was determined
by liquid scintillation spectroscopy as described above. Specific
GTPase activity was calculated as the difference between total activity
and background activity, obtained in the absence of sarcolemmal
membranes in the assay. "Basal" GTPase activity is defined as
activity in the absence of a receptor agonist (carbachol).
The values of GTPase activity as well as the enzyme characteristics measured in the present study under control conditions were similar to those previously reported by Fleming and Watanabe.13 Basal (in the absence of carbachol) and total (in the presence of 1 mmol/L carbachol) GTPase activity were linearly dependent on protein concentration (0.8 to 6.0 µg per assay). The amount of hydrolyzed GTP linearly increased within the time range from 1 to 30 minutes in the presence and absence of carbachol under control conditions as well as after 15 minutes of ischemia. The dependence of basal and total GTPase activity on GTP concentration also exhibited saturation kinetics and was measured under ischemic and nonischemic conditions (see "Results"). The effect of carbachol (1 mmol/L) on high-affinity GTPase activity was blocked completely by the addition of 100 µmol/L atropine sulfate.
Treatment of Sarcolemmal Vesicles With Alamethicin
The sidedness of the present preparation of sarcolemmal
vesicles has been extensively studied by Colvin et al12
under control conditions. To exclude unspecific effects resulting from
different amounts of latent enzyme activities due to different
sidedness of vesicles gained from ischemic and nonischemic tissues,
most experiments were performed in the presence of the antibiotic
ionophore alamethicin. Alamethicin was preincubated with sarcolemmal
membranes (20 minutes, 25°C; wt alamethicin/wt protein=1.0) before
starting the biochemical reaction.
Adenylyl Cyclase
Adenylyl cyclase activity was determined by measuring the
conversion of [
-32P]ATP to [32P]cAMP
according to Jakobs et al.14 The assay volume was 100
µL, containing 0.1 mmol/L ATP with 2x105 cpm of
[
-32P]ATP, 5 mmol/L MgCl2, 0.1
mmol/L cAMP, 10 µmol/L GTP, 1 mmol/L EDTA, 0.5 mmol/L dithiothreitol,
5 mmol/L creatine phosphate, 2 U creatine kinase, 0.05 mg bovine serum
albumin, and 75 mmol/L Tris HCl (pH 7.6). The reaction was started by
the addition of sarcolemmal membranes (2.0 to 3.0 µg protein) and
continued for 10 minutes at 37°C. Specific adenylyl cyclase activity
was calculated as the difference between total activity and background
activity, obtained in the absence of sarcolemmal membranes in the
assay. To unmask latent adenylyl cyclase activity, membranes (2.0 to
3.0 µg protein) were preincubated with alamethicin for 20 minutes
at 25°C as described above. A sample that contained
[3H]cAMP instead of labeled ATP was run in parallel to
determine the yield of cAMP in the assays. Under these conditions
adenylyl cyclase activity was linear with time (1 to 20 minutes) and
protein content (0.1 to 3.0 µg). Carbachol (1 mmol/L)mediated
effects on adenylyl cyclase activity were blocked completely by the
addition of 100 µmol/L atropine sulfate.
Experiments with sham-operated animals showed that there was no inherent difference of specific adenylyl cyclase activity between the left ventricular anterior and posterior walls. Furthermore, adenylyl cyclase activity was similar in the control area of the left ventricular posterior wall regardless of whether the LAD was ligated or not. The use of highly purified sealed sarcolemmal vesicles and alamethicin, which was added to each assay to unmask latent enzyme activities, was associated with an increased variability of basal adenylyl cyclase activity (defined as activity in the presence of 10 µmol/L GTP and absence of a receptor ligand) among different assays (see "Results"). However, the SD within each assay (triplicate determinations) did not exceed 5% of the mean value. Hence, since each animal served as its own control and membrane preparation and all assays were run in parallel for every animal, the effects of ischemia and reperfusion were highly reproducible, with only slight variations among all animals studied.
Quantification of Gi
,
Gi
2, and Gs
Sarcolemmal proteins were separated by disc sodium dodecyl
sulfate (SDS)polyacrylamide gel electrophoresis. Thirty micrograms of
sarcolemmal proteins was suspended in 200 µL buffer containing 2%
SDS, 40 mmol/L Tris HCl (pH 6.8), 10% glycerol, 0.006% bromphenol
blue (solubilized in ethanol), and 256 mmol/L ß-mercaptoethanol
before application to the gel. For reference, molecular weight
standards (30 to 200 kD) and transducin were used. Electrophoresis was
performed for 6 hours with a current of 30 mA with a running buffer
consisting of 0.1% SDS, 200 mmol/L glycine, and 25 mmol/L Tris HCl.
The separated proteins were transferred to nitrocellulose filters BA 83
(Schleicher & Schüll) with a transfer buffer consisting of 27.5
mmol/L Tris HCl, 190 mmol/L glycine, and 20% methanol. Unspecific
binding sites of nitrocellulose were blocked by 2.5% bovine serum
albumin in 0.9% NaCl and 50 mmol/L Tris HCl (pH 7.4). The
nitrocellulose filters then were incubated for 3 hours at room
temperature with specific peptide antibodies against Gs
and Gi
(NENDu Pont). Both primary antisera were probed
with the nitrocellulose blots simultaneously. The antibody against
Gi
is specific for the subtypes 1 and 2, cross-reacts
with transducin, and does not recognize Gi
3 or
Go. The amount of Gs
and Gi
on the nitrocellulose filters was visualized by autoradiography with
protein A-3-(4-hydroxy,5-[125I]iodo-phenyl)propionamid as
radioactive marker. Unspecific binding of labeled protein A was
eliminated by washing the filters three times with a solution
consisting of 150 mmol/L NaCl, 20 mmol/L Tris HCl (pH 7.4). The
nitrocellulose filters then were exposed at -80°C for 3 days with
the use of Kodak X-Omat films. The autoradiograms were analyzed by
computer-assisted laser densitometry (LKB-2400-Gel-Scan XL, Fa
Pharmacia). Quantitative analysis revealed that Western blot
analysis was linear in a range of 10 to 100 µg sarcolemmal
proteins applied (data not shown). Because myocardial Gi
is predominantly represented by the subunit
Gi
2,15 this procedure was repeated
with the same immunoblots after washing off previous peptide antibodies
specific for Gi
1,2 (and Gs
) with
glycine (0.1 mol/L, pH 2.5, 1 hour). Completion of the washing
procedure was verified by autoradiograms after incubating the
nitrocellulose filters with [125I]protein A. Thereafter,
the washed nitrocellulose blots were exposed to the specific antibodies
against subtype Gi
2. The following labeling of the
membranes with Gi
2 and [125I]protein A was
as described above.
Samples from the control and ischemic areas of the same heart were always run in parallel in the same experiment, using the same primary antiserum.
Experimental Protocol
A total of 54 animals were studied. Seven animals were
sham-treated, and 47 animals were used for the interventions. The
following protocols were used: 5 minutes of ischemia (n=9); 15 minutes
of ischemia (n=10); 15 minutes of ischemia/60 minutes of reperfusion
(n=5); 5 minutes of ischemia/15 minutes of reperfusion (n=8); and 5
minutes of ischemia/15 minutes of reperfusion/5 minutes of ischemia
(n=15).
Because of the small sample size within the ischemic myocardium and the low yield of sarcolemmal protein from the purification, not all experiments could be performed with each animal. Carbachol-stimulated GTPase and/or adenylyl cyclase inhibition was determined in all animals. Binding of [3H]N-methylscopolamine was determined in 4 dogs subjected to 15 minutes of ischemia. Quantification of Gi proteins was assessed in 6 animals subjected to 15 minutes of ischemia (n=3 for pertussis toxincatalyzed ADP ribosylation and immunoblotting with Gi1,2- and Gi2-specific antibodies, respectively).
The experiments to assess the interaction between receptor and G
protein were carried out in 14 animals, as follows: (1) high- and
low-affinity binding sites for carbachol: n=4, 5 minutes of ischemia;
(2) carbachol-stimulated binding of [
-35S]GTP: n=4, 15
minutes of ischemia; (3) EC50 for carbachol-stimulated
GTPase: n=4, 15 minutes of ischemia; and (4) substrate dependency of
the high-affinity GTPase with and without carbachol: n=3, 15 minutes of
ischemia.
Data Analysis
All values are given as mean±SD. Student's paired t
test was commonly used for statistical analysis. Statistical
analysis of the dose-response effects (Figs 4
, 6
, and 7
) was
performed by means of ANOVA followed by the Student-Newman-Keuls test.
Each dog used in this study served as its own control in that the
results obtained from the left ventricular posterior wall (control
area) were compared with those obtained from the myocardial area
supplied by the LAD. For each series of experiments a total of at least
four measurements with different membrane preparations from at least
three animals were performed; n always indicates the number of
individual animals in each set of experiments. Furthermore, all
experiments were carried out by means of triplicate determinations. The
SD within each triplicate determination in the assay did not exceed 5%
of the mean value.
|
|
|
Materials
All chemicals were reagent grade.
[3H]N-methylscopolamine,
guanosine-5'-[
-32P]triphosphate,
[
-35S]guanosine-5'-O-(3-thiotriphosphate), and
antibodies against Gi
1,2 and Gs
were
obtained from NENDu Pont. Unlabeled nucleotides were obtained from
Boehringer. If not indicated otherwise in the text, the other chemicals
were purchased from Sigma Chemie GmbH. Antibodies against
Gi
2 were obtained from Gramsch Laboratories.
| Results |
|---|
|
|
|---|
|
After 15-minute ligation of the LAD, neither binding capacity nor
binding affinity of muscarinic receptors was changed (Table 1
, Fig 1
; n=4). Unspecific binding was <10% of total binding
and did not change under ischemic conditions.
|
Binding of Carbachol
Under control conditions and after 5 minutes of ischemia,
computerized curve-fitting analysis detected two binding states for
carbachol (control: Kdhigh=36.7 nmol/L, 62% of
total binding capacity, Kdlow=3.3 µmol/L;
ischemia: Kdhigh=36.8 nmol/L, 68% of total
binding capacity, Kdlow=6.1 µmol/L; Fig 2
). Under both conditions the presence of Gpp(NH)p
resulted in a conversion of high-affinity sites to low-affinity sites.
According to curve-fitting analysis, in the presence of Gpp(NH)p
the two-site model was not superior to the onebinding site model
(control: Kd=1.2 µmol/L; ischemia:
Kd=0.9 µmol/L; Fig 2
; n=4). Similar results
were obtained in sham-treated animals (n=4) in membranes obtained from
the anterior and posterior left ventricular wall.
|
Binding of [
-35S]GTP
Binding of [
-35S]GTP to sarcolemmal
membranes was studied up to a concentration of 30 nmol/L.
Carbachol stimulated the binding of [
-35S]GTP to
sarcolemmal membranes only at low concentrations of
[
-35S]GTP. The maximal carbachol-induced increase in
[
-35S]GTP binding was observed at 2 nmol/L of
[
-35S]GTP. At higher concentrations (15 to 30 nmol/L)
carbachol-stimulated binding was no longer observed, indicating that
carbachol only increased binding affinity without affecting binding
capacity for [
-35S]GTP. In addition, at concentrations
>4 to 8 nmol/L, binding of [
-35S]GTP reincreased
because of the coexistence of distinct binding sites in the sarcolemmal
membranes. After 15 minutes of myocardial ischemia, neither basal nor
carbachol (1 mmol/L)stimulated [
-35S]GTP binding was
significantly changed (Table 2
). These data were
obtained by Scatchard analysis of the high-affinity binding site.
Unspecific binding of [
-35S]GTP was <10% of total
binding and similar under both conditions. Similar results were
obtained with sham-treated animals (n=4).
|
Quantification of G Proteins
Western blot analysis that used specific peptide antibodies
resulted in single bands with a molecular weight of 38 kD for
transducin, 41 kD for Gi
, and 42 kD for
Gs
. Quantitative analysis of the amount of
Gi
1,2 and Gs
in sarcolemmal membranes did
not reveal significant differences between the ischemic and the
nonischemic areas of the left ventricle (Fig 3
).
Similarly, comparing the nonischemic myocardium of the left and the
right ventricles with the ischemic myocardial area of the anterior wall
of the left ventricle, subgroup analysis that used specific
antibodies against Gi
2 did not reveal significant
differences in the amount of Gi
2 (Table 3
).
|
|
In accordance with these results, pertussis toxincatalyzed ADP ribosylation of sarcolemmal proteins remained unchanged after 15 minutes of ischemia.16
GTPase Activity
Control Group
Basal GTPase activity, defined as the enzymatic activity in
the absence of carbachol, was 27.4±3.5
pmol · min-1 · mg protein-1 in
controls (posterior wall of the left ventricle; n=4). Similar values
were obtained from the anterior wall of the left ventricle in
sham-operated animals (28.3±3.1 pmol · min-1 · mg
protein-1; n=4).
High-Affinity GTPase Activity During a Single Period of
Ischemia
Fifteen-minute ligation of the LAD resulted in a 23% reduction of
basal GTPase activity in sarcolemmal membranes obtained from the
anterior wall (21.1±2.2 pmol · min-1 · mg
protein-1; n=4; P<.05 versus control; Fig 4
).
GTPase activity could be stimulated in a dose-dependent manner by the
muscarinic receptor agonist carbachol in both nonischemic and ischemic
myocardium (Fig 4
). The concentration of carbachol needed for half
maximal stimulation was similar under both conditions (control,
8.7±6.3 µmol/L; 15 minutes of ischemia, 5.1±2.0 µmol/L;
P=NS). Total GTPase activity in the presence of 1 mmol/L
carbachol was 38.4±3.5 pmol · min-1 · mg
protein-1 at control conditions and 27.6±2.0
pmol · min-1 · mg protein-1 after 15
minutes of ischemia (n=4; P<.05 ischemia versus control;
Fig 4
).
The amount of muscarinic receptorcoupled GTPase activity (total
GTPase activity in the presence of carbachol minus basal GTPase
activity) was significantly reduced by 45% after ischemia (control,
11.0±1.6 pmol · min-1 · mg
protein-1; ischemia, 6.5±1.4
pmol · min-1 · mg protein-1;
P<.05; carbachol concentration, 1 mmol/L; Fig 4
).
Treatment of sarcolemmal membranes with alamethicin resulted in a
twofold to fivefold increase of basal and total GTPase activity after
stimulation with carbachol (Fig 4
, inset). After 5 (n=9) and 15 (n=6)
minutes of ischemia, the amount of muscarinic receptorcoupled GTPase
activity (total GTPase activity in the presence of carbachol minus
basal GTPase activity) again was significantly decreased by 39% to
46% compared with the control area (Figs 5
, 6
, and 8
). Between 5 and
15 minutes there was no significant progression of ischemia-induced
GTPase impairment (Fig 5
).
|
|
The dependence of high-affinity GTPase activity on GTP concentration,
measured in the presence of alamethicin, exhibited saturation
kinetics (Km=192±11 nmol/L;
Vmax=138±16 pmol · min-1 · mg
protein-1; n=3). Carbachol increased maximal velocity but
did not change Km; ie, the GTP
concentration needed for half maximal velocity remained unchanged
(Km=200±14 nmol/L, P=NS;
Vmax=218±20 pmol · min-1 · mg
protein-1, P<.05 [plus carbachol
versus without carbachol]; n=3). The ischemia-induced inhibition of
GTPase activity exhibited the characteristics of a noncompetitive
inhibition; ie, Vmax was reduced, whereas
Km remained unchanged
(Km=185±15 nmol/L; Vmax
without carbachol=102±13 pmol · min-1 · mg
protein-1, P<.05 [ischemia versus
control]; Vmax plus carbachol=154±19
pmol · min-1 · mg protein-1,
P<.05 [ischemia versus control]; n=3; Fig 6
).
Carbachol-Stimulated GTPase Activity After a Single Period of
Ischemia Followed by Reperfusion
When the LAD was ligated for 15 minutes and subsequently
reperfused for 1 hour, the ischemia-induced reduction of GTPase
activity was not observed. The level of carbachol-stimulated GTPase
activity in the area of intervention exceeded the GTPase activity of
the control area by 20% (control, 18.0±2.4; reperfusion, 22.4±3.2
pmol · min-1 · mg protein-1,
no alamethicin added; n=5; P<.05; Fig 7
).
When the 5-minute ischemic period was followed by 15 minutes of
reperfusion, carbachol-stimulated GTPase activity in the reperfused
area again exceeded the activity in the control area (33.7±20.6 versus
49.1±22.5 pmol · min-1 · mg
protein-1; n=7; P=.012; Fig 8
).
Carbachol-Stimulated GTPase Activity During a Second Period of
Ischemia After a Short Period of Ischemia and Reperfusion
After 5 minutes of ischemia followed by 15 minutes of reperfusion,
a second 5-minute period of ischemia was induced. During this second
ischemic period carbachol-stimulated GTPase activity remained elevated
(38.4± 16.7 versus 49.2±20.1 pmol · min-1 · mg
protein-1; n=13; P=.009; Fig 8
).
Isoproterenol-Induced Adenylyl Cyclase Stimulation
Stimulation of GTP-activated adenylyl cyclase by a submaximally
active concentration of the ß-receptor agonist isoproterenol was not
affected by the first or second ischemic period or during reperfusion.
After 5 minutes of ischemia, basal adenylyl cyclase activity in the
presence of 10 µmol/L GTP increased to 228% by the addition of 100
µmol/L isoproterenol (control, from 382±147 to 869±290
pmol · min-1 · mg protein-1;
ischemia, from 258±112 to 609±225
pmol · min-1 · mg protein-1). In the
reperfusion group, adenylyl cyclase activity was increased to 223%
(control, from 422±272 to 807±485
pmol · min-1 · mg protein-1;
reperfusion, from 328±290 to 751±759
pmol · min-1 · mg protein-1), and in
the preconditioned group it was increased to 247% by the addition of
isoproterenol (control, from 541±254 to 1349±807
pmol · min-1 · mg protein-1;
preconditioning, from 388±203 to 1024±730
pmol · min-1 · mg protein-1).
Carbachol-Induced Adenylyl Cyclase Inhibition
Maximal inhibition of isoproterenol (100 µmol/L)stimulated
adenylyl cyclase activity by carbachol was determined. The decrease in
carbachol-stimulated GTPase activity observed during 5 minutes of
ischemia was accompanied by a similar decrease of the carbachol-induced
adenylyl cyclase inhibition. Carbachol reduced isoproterenol-stimulated
adenylyl cyclase activity by 28.9±2.4% from 869±290 to 617±192
pmol · min-1 · mg protein-1 in the
control group and by 15.1±2.6% from 609±225 to 517±172
pmol · min-1 · mg protein-1 during 5
minutes of ischemia (Fig 9
; n=5;
P<.001).
|
The increased carbachol-stimulated GTPase activity during the
reperfusion period was accompanied by a similar increase in maximal
carbachol-induced adenylyl cyclase inhibition. Carbachol reduced
isoproterenol-stimulated adenylyl cyclase activity by 21±6.8% from
807±485 to 636±374 pmol · min-1 · mg
protein-1 in the control group and by 26.4±7.6% from
751±759 to 553±579 pmol · min-1 · mg
protein-1 in the reperfusion group (n=8;
P=.016; Fig 9
). This increased inhibition of adenylyl
cyclase activity was also maintained during a second period of
ischemia. Carbachol reduced isoproterenol-stimulated adenylyl
cyclase activity by 24.2±6.8% from 1349±807 to 1022±672
pmol · min-1 · mg protein-1 in the
control group and by 28.6±8% from 1024±730 to 737±537
pmol · min-1 · mg protein-1 in the
preconditioned group (n=15; P=.003; Fig 9
).
Time to Onset of Ischemia-Induced ST-Segment Deviation
The onset of significant ST-segment deviation (>0.1 mV) in the
surface ECG was determined during the initial preconditioning ischemia
and compared with the second ischemic period. During the initial
ischemic period, the onset of significant ST-segment deviations was
observed after 44±20 seconds. During the subsequent second 5-minute
period of ischemia, the onset of ST-segment deviations was delayed,
occurring after 93±37 seconds (n=5; P=.036).
| Discussion |
|---|
|
|
|---|
-subunits of heterotrimeric G proteins. Only the high-affinity
GTPase responds to stimulation by receptor agonists. By evaluating the
carbachol-stimulated GTPase activity (GTPase activity in the presence
of carbachol minus basal GTPase activity), only the GTPase of G
proteins coupling to muscarinic receptors is assessed. Muscarinic
receptorstimulated high-affinity GTPase in cardiac sarcolemma has
been demonstrated to be susceptible to pertussis toxin and furthermore
to be closely related to inhibition of adenylyl cyclase.13
Hence, carbachol-stimulated GTPase activity is predominantly expressed
by Gi proteins.
Within the cycle of G protein activation and inactivation, the GTPase
activity of the
-subunit is the inactivation mechanism
("turn-off" reaction). However, measurement of the
carbachol-stimulated GTPase reaction is a reflection of
hormone-stimulated GDP release with resulting stimulation of GTP
binding and hydrolysis. Hence, it is a direct measure of muscarinic
stimulation of the G protein. Accordingly, the changes in GTPase
activity due to ischemia or reperfusion were accompanied by concordant
changes in adenylyl cyclase inhibition, indicating that the altered
activation of the G protein cycle led to alterations of the effector
regulation.
During ischemia, activation of Gi proteins is expected to be predominantly induced by activation of adenosine A1 receptors, due to the increased myocardial release of adenosine. With regard to the mechanisms underlying ischemic preconditioning, however, the activation of Gi proteins rather than activation of adenosine A1 receptors seems crucial in that ischemic preconditioning is lost after pretreatment with pertussis toxin.5 Pertussis toxin does not interact with the receptor but catalyzes ADP ribosylation of Gi and Go proteins, thereby uncoupling them from receptor-mediated activation. In addition, cardioprotection during ischemia can be induced by pretreatment with carbachol as well as with A1 agonists.
Because of the very low density of adenosine receptors in sarcolemmal
membranes from canine ventricles (
25 fmol/mg protein in the membrane
preparations used in this study; data not shown) and the low yield of
sarcolemmal protein from the small ischemic area (1.5 to 2.5 g of
tissue), it was not possible to assess the characteristics of the
adenosine A1 receptorcoupled signal transduction in this
set of experiments. In contrast, M2 receptor density in
these purified sarcolemmal membranes amounts to 3 pmol/mg protein
(Table 1
), and M2-mediated signal transduction is easily
assessable. Therefore, in this study the responsiveness of
Gi-mediated signal transduction toward receptor activation
was studied with the use of the M2 agonist carbachol. The
detection of carbachol-stimulated high-affinity GTPase activity
afforded the use of a highly purified membrane preparation. Despite the
advantages of using highly purified membrane preparations, it is
recognized that the purification steps are associated with a loss of
membrane proteins, including fractions of the signal transduction
components studied here.
Impaired Gi-Mediated Signal Transduction During
Ischemia
During early myocardial ischemia, the activation of
adrenergic receptors is increased because of an accumulation of
catecholamines in the interstitial space.17 In addition,
the sensitivity of adrenergic signal transduction may be likewise
augmented due to a paradoxical increase in
- and ß-adrenergic
receptor density18 19 and a receptor-independent
sensitization of adenylyl cyclase.20 Activation of
adrenergic receptors leads to an increased energy demand with extension
of myocardial necrosis21 and may induce malignant
ventricular tachyarrhythmias.22 23
Under physiological conditions, an effective endogenous control system exists to antagonize excessive adrenergic signal transduction. This endogenous antagonism of adrenergic signal transduction is mediated by Gi proteins, which can be activated by various receptors such as adenosine A1 and muscarinic M2 receptors. Although a sufficient amount of adenosine for maximal activation of A1 receptors is already released during the first minutes of myocardial ischemia, the endogenous antagonism of adrenergic signal transduction remains insufficient, and exogenous antagonism with ß-adrenergic receptor blocking agents remains an effective therapeutic approach.24 This may indicate an impaired signal transduction of Gi proteins during early myocardial ischemia. This concept is supported by the finding that the inhibition of canine cardiac adenylyl cyclase is significantly reduced during the first 5 minutes of myocardial ischemia.16
The activation of Gi proteins leads to a regulation of various effectors, eg, the inhibition of adenylyl cyclase. In addition, Gi proteins mediate activation of atrial potassium channels,25 activation of ventricular ATP-sensitive potassium channels,26 direct inhibition of L-type calcium channels,27 and inhibition of the isoproterenol-stimulated sodium current.28 ATP-sensitive potassium channels may be of major importance because ischemic preconditioning is lost after pretreatment with glibenclamide,29 an inhibitor of these channels. However, in rabbits blockade of the ATP-dependent potassium channels did not prevent ischemic preconditioning.30 Potentially, the increased Gi-mediated regulation of any of the aforementioned effectors could be "protective" during ischemia by decreasing excessive calcium loading and cellular energy demand and by increasing electric stability.
An impairment of the Gi-mediated signal transduction during ischemia, as shown in this study, would hamper the potential benefit of a cholinergic system activation, which has been shown to prevent ischemia-induced malignant tachyarrhythmias.31 32 33 34 35 36 Accordingly, as shown in an earlier study, carbachol elevated the ventricular fibrillation threshold in nonischemic but not in ischemic areas of canine ventricular myocardium.37 Furthermore, it recently has been shown that carbachol-mediated inhibition of postsynaptic norepinephrine release is attenuated in the ischemic myocardium.38
The ischemia-induced impairment of muscarinic receptor signal
transduction could be attributed neither to a reduction of muscarinic
receptor density or affinity nor to an impaired interaction between
muscarinic receptors and inhibitory G proteins, since muscarinic
receptorstimulated GTP binding, agonist binding to muscarinic
receptors, and the EC50 for stimulation of GTPase by
carbachol all remained unaltered during ischemia. It is known that
unoccupied receptors can stimulate basal high-affinity GTPase
activities. This activity of unoccupied receptors can be reversed with
specific receptor antagonists. A decrease of this "empty
receptor" activation of Gi proteins as the cause of
decreased basal high-affinity GTPase activity during ischemia was
excluded because atropine decreased high-affinity GTPase activity
similarly in ischemic and nonischemic membranes. A specific,
ischemia-induced loss of the
-subunit population of inhibitory G
proteins was also excluded. Although no direct assessment of the levels
of ß
-subunits was performed, a selective loss of these subunits
despite unchanged levels of the
-subunit within 5 minutes of
ischemia is very unlikely and should have been detected by
autoradiography that used pertussis toxin for the labeling of
Gi proteins with [32P]ADP.16
This is because pertussis toxin catalyzes only the ADP ribosylation of
the complete heterotrimeric G protein. In addition,
carbachol-stimulated binding of [
-S]GTP would be altered by a
selective loss of ß
-subunits because the receptor can interact
only with the heterotrimeric G protein.39 A selective loss
of ß
-subunits, relevant to Gi-mediated signal
transduction, would reduce the availability of heterotrimeric G
proteins, leading to a decrease in receptor-stimulated binding of
[
-S]GTP.
From the above findings it may therefore be concluded that reduced
carbachol-stimulated high-affinity GTPase activity is the result of a
reversible change of Gi protein function that involves
reaction steps after GTP binding. It has been shown that after binding
of GTP, G proteins must undergo at least one other reaction step, which
is associated with subunit dissociation, before they can interact with
their responsive effectors. This reaction step is rate limiting for the
activation of the G protein. The noncompetitive characteristics of
ischemia-induced inhibition of GTPase (Fig 6
) indicate that a part of
the available enzyme pool may be reversibly converted to a functional
state that is able to bind GTP but that cannot be activated to mediate
inhibition of adenylyl cyclase and subsequently catalyze GTP
hydrolysis. The characteristics of such a hypothetical functional state
of Gi proteins would resemble those recently observed with
the mutant cell line H21a.40 Reduction of muscarinic
receptorcoupled GTPase activity is a rapid event; it could be
observed after 5 minutes of ischemia with no further progression if
ischemia was prolonged up to 15 minutes.
In conclusion, the present results suggest an ischemia-induced functional alteration of inhibitory G proteins leading to an impairment of muscarinic receptormediated signal transduction.
Increased Gi-Mediated Signal Transduction During
Reperfusion and Second Ischemia
Several previous studies did not differentiate between the
mechanism initiating ischemic preconditioning (during the
preconditioning brief period of ischemia) and the protective mechanism
during the subsequent sustained ischemic period. More recently it has
been shown that a continued activation of A1 receptors
during sustained ischemia is required for the protective mechanism of
ischemic preconditioning.7 Maximal activation of adenosine
A1 receptors is obtained at concentrations of
100 nmol/L
adenosine.9 During myocardial ischemia (even in the
absence of preconditioning), interstitial adenosine concentration is in
the micromolar range.8 Hence, it can be assumed that the
effect of preconditioning may be due to an increased responsiveness of
the adenosine A1 receptor pathway. Although several
findings suggest that the release of adenosine during the preceding
brief period of ischemia is essential for the initiation of ischemic
preconditioning in most species (except in rats41 ), the
present study emphasizes the importance of the reperfusion period
for the protective mechanism of preconditioning. The responsiveness of
Gi-mediated signal transduction increases only on
reperfusion, whereas it decreases during the initial period of
ischemia.
Regarding ischemic preconditioning, as stated above, a continued activation of adenosine A1 receptors is required for the protective mechanism. In the present study an increased responsiveness of Gi proteins toward receptor activation during reperfusion and during a second ischemic period was accompanied by an increased carbachol-mediated inhibition of adenylyl cyclase. The relevance of adenylyl cyclase inhibition for the protective mechanism during ischemic preconditioning is not yet established. Indirect evidence may be derived from findings that administration of ß-adrenergic receptor blocking agents reduce infarct size42 and mortality from myocardial infarction,24 whereas activation of ß-adrenergic receptors and an intracellular increase of cAMP during ischemia are associated with an increase in life-threatening ventricular arrhythmias22 23 and an extension of myocardial necrosis.21
Although it is not definitely known which of the Gi-regulated effectors are involved in the cardioprotective mechanism of ischemic preconditioning, the present study suggests that Gi proteins are sensitized during reperfusion after a single 5-minute period of ischemia and maintain an increased responsiveness toward receptor activation during a following period of ischemia. This sensitization leads to an improved adenylyl cyclase inhibition and may involve other effectors as well.
| Acknowledgments |
|---|
Received February 14, 1994; accepted January 23, 1995.
| References |
|---|
|
|
|---|
2.
Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic
preconditioning slows energy metabolism and delays ultrastructural
damage during a sustained ischemic episode. Circ
Res. 1990;66:913-931.
3.
Shiki K, Hearse DJ. Preconditioning of ischemic
myocardium: reperfusion induced arrhythmias. Am J
Physiol. 1987;253:H1470-H1476.
4.
Liu GS, Thornton J, Van Winkle DM, Stanley AWH, Olsson RA,
Downey JM. Protection against infarction afforded by preconditioning is
mediated by A1 adenosine receptors in rabbit heart.
Circulation. 1991;84:350-356.
5. Thornton JD, Liu GS, Downey JM. Pretreatment with pertussis toxin blocks the protective effects of preconditioning: evidence for a G-protein mechanism. J Mol Cell Cardiol. 1993;25:311-320. [Medline] [Order article via Infotrieve]
6.
Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous
pretreatment with A1-selective adenosine analogues protects
the heart against infarction. Circulation. 1992;85:659-667.
7.
Toombs CF, McGee DS, Johnston WE, Vinten-Johanson J.
Myocardial protective effects of adenosine: infarct size reduction with
pretreatment and continued receptor stimulation during ischemia.
Circulation. 1992;86:986-994.
8.
Olsson RA. Changes in content of purine nucleoside in canine
myocardium during coronary occlusion. Circ Res. 1970;26:301-306.
9.
Londos C, Cooper DMF, Schlegel W, Rodbell M. Adenosine
analogs inhibit adipocyte adenylate cyclase by a GTP-dependent process:
basis for actions of adenosine and methylxanthines on cyclic AMP
production and lipolysis. Proc Natl Acad Sci U S A. 1978;75:5362-5366.
10.
Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross
J Jr, Braunwald E. Factors influencing infarct size following
experimental coronary artery occlusions.
Circulation. 1971;43:67-82.
11.
Jones LR, Maddock SW, Besch HR Jr. Unmasking effect of
alamethicin on the (Na+,K+)-ATPase,
beta-adrenergic receptor-coupled adenylate cyclase, and cAMP-dependent
protein kinase activities of cardiac sarcolemmal vesicles. J Biol
Chem. 1980;255:9971-9980.
12. Colvin RA, Ashavaid TF, Herbette LG. Structure-function studies of canine cardiac sarcolemmal membranes, I: estimation of receptor site densities. Biochim Biophys Acta. 1985;812:601-608. [Medline] [Order article via Infotrieve]
13. Fleming JW, Watanabe AM. Muscarinic cholinergic-receptor stimulation of specific GTP hydrolysis related to adenylate cyclase activity in canine cardiac sarcolemma. Circ Res. 1988;64:340-350.
14. Jakobs KH, Saur W, Schultz G. Reduction of adenylate cyclase activity in lysates of human platelets by the alpha-adrenergic component of epinephrine. J Cyclic Nucl Res. 1976;2:381-392.
15.
Holmer RH, Stevens S, Homcy CJ. Tissue- and species-specific
expression of inhibitory guanine nucleotide-binding proteins: cloning
of a full-length complementary DNA from canine heart.
Circ Res. 1989;65:1136-1140.
16. Niroomand F, Bangert M, Beyer T, Rauch B. Reduced adenylyl cyclase inhibition by carbachol and GTP during acute myocardial ischemia. J Mol Cell Cardiol. 1992;24:471-475. [Medline] [Order article via Infotrieve]
17.
Schömig A, Dart AM, Dietz R, Mayer E, Kübler W.
Release of endogenous catecholamines in the ischemic myocardium of the
rat. Circ Res. 1984;55:689-701.
18. Corr PB, Shayman JA, Kramer JB, Kipnis RJ. Increased alpha-adrenergic receptors in ischemic cat myocardium. J Clin Invest. 1981;67:1232-1236.
19. Mukherjee A, Wong TM, Buja M, Lefkowitz RJ. Beta adrenergic and muscarinic cholinergic receptors in canine myocardium: effects of ischemia. J Clin Invest. 1979;64:1423-1428.
20.
Strasser RH, Braun-Dullaeus R, Walendzik H, Marquetant R.
1-receptorindependent activation of protein kinase C
in acute myocardial ischemia: mechanisms for sensitization of the
adenylyl cyclase system. Circ Res. 1992;70:1304-1312.
21.
Schulz R, Guth BD, Pieper K, Martin C, Heusch G. Recruitment
of an inotropic reserve in moderately ischemic myocardium at the
expense of metabolic recovery: a model of short-term hibernation.
Circ Res. 1992;70:1282-1295.
22. Corr PB, Witkowski FX, Sobel BE. Mechanisms contributing to malignant dysrhythmias induced by ischemia in the cat. J Clin Invest. 1987;61:109-119.
23. Podzuweit T, Dalby AJ, Cherry GW, Opie LH. Cyclic AMP levels in ischemic and non-ischemic myocardium following coronary artery ligation: relation to ventricular fibrillation. J Mol Cell Cardiol. 1978;10:81-94. [Medline] [Order article via Infotrieve]
24. Hjalmarson Å, Elmfeldt D, Herlitz J, Holmberg S, Málek I, Nyberg G, Rydén L, Swedberg K, Vedin A, Waagstein F, Waldenström A, Waldenström J, Wedel H, Wilhelmsen L, Wilhelmsson C. Effect on mortality of metoprolol in acute myocardial infarction: a double blind randomised trial. Lancet. 1981;2:823-827. [Medline] [Order article via Infotrieve]
25.
Codina J, Yatani A, Grenet D, Brown AM, Birnbaumer L. The
alpha subunit of the GTP binding protein Gk opens atrial
potassium channels. Science. 1987;236:442-445.
26.
Kirsch GE, Codina J, Birnbaumer L, Brown AM. Coupling of
ATP-sensitive K+ channels to A1 receptors by G proteins in
rat ventricular myocytes. Am J Physiol. 1990;259:H820-H826.
27. Keung CE, Karliner JS. Complex regulation of calcium current in cardiac cells. J Clin Invest. 1990;85:950-954.
28.
Matsuda JJ, Lee HC, Shibata EF. Acetylcholine reversal of
isoproterenol-stimulated sodium currents in rabbit ventricular
myocytes. Circ Res. 1993;72:517-525.
29.
Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium
channels prevents myocardial preconditioning in dogs.
Circ Res. 1992;70:223-233.
30.
Thornton JD, Thornton CS, Sterling DL, Downey JM. Blockade of
ATP-sensitive potassium channels increases infarct size but does not
prevent preconditioning in rabbit hearts. Circ
Res. 1993;72:44-49.
31.
Myers RW, Pearlman AS, Hyman RM, Goldstein RA, Kent KM,
Goldstein RE, Epstein SE. Beneficial effects of vagal stimulation and
bradycardia during experimental acute myocardial ischemia.
Circulation. 1974;49:943-947.
32.
Corr PB, Gillis RA. Role of the vagus nerve in cardiovascular
changes induced by coronary occlusion.
Circulation. 1974;49:86-97.
33.
Zuanetti G, De Ferrari GM, Priori SG, Schwartz PJ. Protective
effect of vagal stimulation on reperfusion arrhythmias in cats.
Circ Res. 1987;61:429-435.
34. Bigger TJ, Kleiger RE, Fleiss JL, Rolnitzky LM, Steinman AB, Miller JP. The multicenter post-infarction research group: components of heart rate variability measured during healing of acute myocardial infarction. Am J Cardiol. 1988;61:208-215. [Medline] [Order article via Infotrieve]
35.
Collins MN, Billman GE. Autonomic response to coronary
occlusion in animals susceptible to ventricular fibrillation. Am
J Physiol. 1989;257:H1886-H1894.
36. Billman GE. Effect of carbachol and cyclic GMP on susceptibility to ventricular fibrillation. FASEB J. 1990;4:1668-1673. [Abstract]
37. Yoon MS, Han J, Tse WW, Rogers R. Effects of vagal stimulation, atropine, and propranolol on fibrillation threshold of normal and ischemic ventricles. Am Heart J. 1977;93:60-65. [Medline] [Order article via Infotrieve]
38.
Du XJ, Dart AM, Riemersma RA, Oliver MF. Failure of the
cholinergic modulation of norepinephrine release during acute
myocardial ischemia in the heart. Circ Res. 1990;66:950-956.
39. Asano T, Pedersen SE, Scott CW, Ross EM. Reconstitution of catecholamine-stimulated binding of guanosine 5'-O-(3-thiotriphosphate) to the stimulatory GTP-binding protein of adenylate cyclase. Biochemistry. 1984;23:5460-5467. [Medline] [Order article via Infotrieve]
40.
Bourne HR, Masters SB, Miller RT, Sullivan KA, Heideman W.
Mutations probe structure and function of G-protein
chains.
Cold Spring Harb Symp Quant Biol. 1988;53:221-228.
41. Li Y, Kloner RA. Ischemic preconditioning is not mediated by adenosine receptors in the rat heart. Circulation. 1992;86(suppl I):I-24. Abstract.
42. Wappel M, Zalewski A, Savage M, Hessen S, Goldberg S, Maroko PR. Myocardial salvage after regional beta adrenergic blockade. Am Heart J. 1989;117:37-42.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
S. Tommasi, E. Carluccio, M. Bentivoglio, L. Corea, and E. Picano Low-dose dipyridamole infusion acutely increases exercise capacity in angina pectoris: A double-blind, placebo controlled crossover stress echocardiographic study J. Am. Coll. Cardiol., January 1, 2000; 35(1): 83 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. J. Schultz, A. K. Hsu, J. T. Barbieri, P.-L. Li, and G. J. Gross Pertussis toxin abolishes the cardioprotective effect of ischemic preconditioning in intact rat heart Am J Physiol Heart Circ Physiol, August 1, 1998; 275(2): H495 - H500. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Domenech, P. Macho, D. Velez, G. Sanchez, X. Liu, and N. Dhalla Tachycardia Preconditions Infarct Size in Dogs : Role of Adenosine and Protein Kinase C Circulation, March 3, 1998; 97(8): 786 - 794. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Mizumura, J. A. Auchampach, J. Linden, R. F. Bruns, and G. J. Gross PD 81,723, an Allosteric Enhancer of the A1 Adenosine Receptor, Lowers the Threshold for Ischemic Preconditioning in Dogs Circ. Res., September 1, 1996; 79(3): 415 - 423. [Abstract] [Full Text] |
||||
![]() |
H. Miyawaki, X. Zhou, and M. Ashraf Calcium Preconditioning Elicits Strong Protection Against Ischemic Injury via Protein Kinase C Signaling Pathway Circ. Res., July 1, 1996; 79(1): 137 - 146. [Abstract] [Full Text] |
||||
![]() |
R. Sandhu, U. Thomas, R. J. Diaz, and G. J. Wilson Effect of Ischemic Preconditioning of the Myocardium on cAMP Circ. Res., January 1, 1996; 78(1): 137 - 147. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |